TY - JOUR
T1 - Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma
T2 - A systematic review and network meta-analysis
AU - Mori, Keiichiro
AU - Yanagisawa, Takafumi
AU - Fukuokaya, Wataru
AU - Iwatani, Kosuke
AU - Matsukawa, Akihiro
AU - Katayama, Satoshi
AU - Pradere, Benjamin
AU - Laukhtina, Ekaterina
AU - Rajwa, Pawel
AU - Moschini, Marco
AU - Albisinni, Simone
AU - Krajewski, Wojciech
AU - Cimadamore, Alessia
AU - Del Giudice, Francesco
AU - Teoh, Jeremy
AU - Urabe, Fumihiko
AU - Kimura, Shoji
AU - Murakami, Masaya
AU - Tsuzuki, Shunsuke
AU - Miki, Jun
AU - Miki, Kenta
AU - Shariat, Shahrokh F.
AU - Kimura, Takahiro
N1 - Publisher Copyright:
© 2023 The Japanese Urological Association.
PY - 2024/1
Y1 - 2024/1
N2 - Adjuvant immune checkpoint inhibitor therapies have radically altered the treatment landscape for renal cell carcinoma and urothelial carcinoma. However, studies have reported negative data regarding adjuvant immune checkpoint inhibitor therapies. Thus, this study aimed to assess the role of adjuvant immune checkpoint inhibitor therapy for both renal cell carcinoma and urothelial carcinoma. A systematic review and network meta-analysis were conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Multiple databases were searched for articles published as of February 2023. Studies were deemed eligible if they evaluated disease-free survival in patients with renal cell carcinoma and urothelial carcinoma receiving adjuvant immune checkpoint inhibitor therapy. Five studies met the inclusion criteria. In a network meta-analysis, pembrolizumab was shown to be the most effective regimen for patients with renal cell carcinoma, whereas nivolumab was found to be the most effective regimen for patients with urothelial carcinoma. Additionally, these results were consistently observed in a sub-analysis of the T stage. The present analysis provides findings that support the usefulness of adjuvant nivolumab therapy in urothelial carcinoma and adjuvant pembrolizumab therapy in renal cell carcinoma, in agreement with the currently available guidelines. However, the caveat is that the randomized controlled trials included in this analysis differed in important respects despite being similar in study design. Therefore, with these differences in mind, care needs to be taken when selecting patients for these immune checkpoint inhibitor therapies to maximize their benefits.
AB - Adjuvant immune checkpoint inhibitor therapies have radically altered the treatment landscape for renal cell carcinoma and urothelial carcinoma. However, studies have reported negative data regarding adjuvant immune checkpoint inhibitor therapies. Thus, this study aimed to assess the role of adjuvant immune checkpoint inhibitor therapy for both renal cell carcinoma and urothelial carcinoma. A systematic review and network meta-analysis were conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Multiple databases were searched for articles published as of February 2023. Studies were deemed eligible if they evaluated disease-free survival in patients with renal cell carcinoma and urothelial carcinoma receiving adjuvant immune checkpoint inhibitor therapy. Five studies met the inclusion criteria. In a network meta-analysis, pembrolizumab was shown to be the most effective regimen for patients with renal cell carcinoma, whereas nivolumab was found to be the most effective regimen for patients with urothelial carcinoma. Additionally, these results were consistently observed in a sub-analysis of the T stage. The present analysis provides findings that support the usefulness of adjuvant nivolumab therapy in urothelial carcinoma and adjuvant pembrolizumab therapy in renal cell carcinoma, in agreement with the currently available guidelines. However, the caveat is that the randomized controlled trials included in this analysis differed in important respects despite being similar in study design. Therefore, with these differences in mind, care needs to be taken when selecting patients for these immune checkpoint inhibitor therapies to maximize their benefits.
KW - adjuvant immunotherapy
KW - renal cell carcinoma
KW - urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85174149406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174149406&partnerID=8YFLogxK
U2 - 10.1111/iju.15319
DO - 10.1111/iju.15319
M3 - Review article
C2 - 37840031
AN - SCOPUS:85174149406
SN - 0919-8172
VL - 31
SP - 25
EP - 31
JO - International Journal of Urology
JF - International Journal of Urology
IS - 1
ER -